Really sick of Bentham Open Spam

Once again, I am getting sick of getting email after email from various Bentham Open Journals like the one below.  This is basically a form of SPAM as they send these out to people no matter what the connection is to the journals field.  I like how they now emphasize that "Please note that submission of a manuscript is not a guarantee for acceptance for publication"
This likely has something to do with the recent controversy over a Bentham Open journal accepting a nonsense paper .
Just goes to show you that just as their are annoying commercial journals and annoying society journals, there certainly are annoying open access journals.  And many Bentham journals take the prize for being as annoying as they come.  Perhaps not all Bentham journals are like this, but I get spam-like email from dozens of them ... and do not get any from other Open Access journals.





Dr. J.A. Eisen
Institute for Genomic Research Rockville MD 20850
United States

Dear Dr. Eisen,

I am writing to you in my capacity as the Editor-in-Chief of Current Molecular Pharmacology, which is a cutting-edge peer-reviewed journal published by Bentham Science Publishers. Bentham Science publishes more than 300 print and open access journals.

Current Molecular Pharmacology is in its second volume and is indexed by all major indexing media includingChemical Abstracts, EMBASEGenamics JournalSeek, Scopus, etc. The journal's homepage may be viewed athttp://www.currmolpharm.org

The journal invites contributions for both comprehensive review articles and guest edited issues in all areas of cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action.

It is a great pleasure to invite you to contribute to Current Molecular Pharmacology. If you wish to submit your work to the journal, then please provide us the title and an abstract (up to 250 words) of your article by email toeditorial@currmolpharm.org You may submit the full article.

Please note that submission of a manuscript is not a guarantee for acceptance for publication, as all manuscripts will be subjected to peer review. Each prospective first-named (corresponding) author will receive a limited number of free reprints and PDF of the paper.

Please could you also refer the journal to your colleagues and other contacts in the field, including your librarian, for promotional purposes. I look forward to hearing from you soon.

Yours sincerely,

Nouri Neamati,
Editor-in-Chief CMP


Here are some comments from FriendFeed

No comments:

Post a Comment